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Primary gastrointestinal lymphoma is a rare disease with no specific clinical presentation. 
Early diagnosis is usually based on suspicious index, otherwise majority of patients present at 
late with very advanced disease with complications. 
The incidence of primary gastrointestinal lymphoma is increasing with HIV disease. 
There are several classification and staging systems with different treatment options varying 
from one center to another. Prognosis depends on the stage at presentation, degree of 
differentiation and age. It was concluded that early diagnosis depends on degree of suspicious 
index with good treatment response. Late presentation is accompanied by marked 
immunosuppresion. Future research needs to determine whether single or combined 
modalities of treatment have good treatment outcomes. A case of primary gastrointestinal 




Primary gastrointestinal lymphoma is a rare 
condition accounting for 0.8-1.2 cases per 
100,000. Gastrointestinal tract is the most 
frequent extra-nodal site of primary 
lymphoma1,2,3,4. 
  
The incidence of primary gastrointestinal or 
hepatic lymphoma is increasingly being seen 
with human immunodeficiency disease5,6,7,8. 
Non-Hodgkin’s lymphoma (NHL) is the 
second most frequent malignancy associated 
with Human Immunodeficiency virus (HIV) 
following Kaposi’s sarcoma. Other 
malignancies include carcinoma of cervix, 
anal canal carcinoma, ocular carcinoma and 
childhood malignancies5,6,9. When evaluating 
AIDS-associated cancers in Sub-Saharan 
Africa it was found that among patients with 
HIV/AIDS; 5.6% have NHL in South Africa, 
2.8% in autopsy study at Ivory Coast, 8.5% 
and 12.4% in 1981 – 1990 and 1991 – 1998 
in Ibadan respectively2. 
 
Majority of patients with primary 
gastrointestinal lymphoma present with late 
advanced disease and complication(s) before 
diagnosis is made. Diagnosis of 
gastrointestinal lymphoma is mainly based on 
suspicious index as there is no specific 
symptom or sign10,11,12. There are several 
different histological classifications, staging 
systems and controversies in the treatment 
options1,2,3,4,5. This prompted the authors to 
report on this case as well as literature review 




T.M aged 48 male, driver, known sero-
positive on Anti-Retro Viral therapy (ARV)-
Trioimune40 for four months, presented with 
gradual onset of epigastric pain for two 
months. Initially pain was dull in nature and 
localized but later on became generalized and 
colicky in nature. He also experienced 
postprandial fullness with little feeds, on and 
off episodes of diarrhoea (3 loose motions per 
day, not bloody or foul smelling) and 
vomiting of recently taken food and 
occasionally bilious vomitus. He reported a 
significant body weight loss with no history 
of haematemesis or maelena. His micturition 
habits were normal and there was no history 
of fever. 
He had been admitted twice at District 
Hospital and twice in Medical Department at 
Muhimbili National Hospital for the same 
complaints with no improvement. He had 
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completed a 9-months course treatment for 
pulmonary tuberculosis therapy in 2001. He 
was married with three children all alive and 
doing well. He took alcohol occasionally but 
he was a non smoker. 
 
Physical examination revealed middle-aged 
man, very weak and dehydrated. He was not 
pale, had no oral thrush and no palpable 
peripheral lymph nodes. Pulse rate was 
80/minute regular and of normal volume. 
Blood pressure was 120/70 mmHg. 
Abdominal examination revealed a full 
abdomen, moving with respiration, visible 
peristalsis from left to right and soft. There 
was a palpable firm, tender, ill defined mass 
in the left hypochondrium. Succussion splash 
was negative. Bowel sounds were normal and 
digital rectal examination revealed normal 
findings. Other systems were found to be 
normal. A provisional diagnosis of Partial 
intestinal obstruction. The cause was 
uncertain 
 
Investigations done during this illness 
included: 
 Chest X-ray, which was normal. A 
repeat after one month was normal 
too. 
 Haemoglobin was 14.2 g/dl, WBC 
count = 8,800cells/cmm, 
ESR=30mm/hr. 
 Serology for H. pylori was negative. 
 Stool analysis revealed E. coli. 
 Urinalysis was normal.  
 Oesophagogastroduodenoscopy 
(OGD) revealed oesophageal 
candidiasis, severe reflux oesophagitis 
and gastritis. 
 Double ELISA test for HIV was 
positive. 
 CD4 count was 180-cells/ µl. Repeat 
CD4 after one month was 284-cells/ 
µl. 
 Abdominal Ultrasonography was 
normal. Repeat after one month was 
normal too. 
 .CT-scan revealed a mass in the right 
hypochondrium (opposite from 
clinical examination) with 
undetermined origin. 
 
Treatment given during this period included 
Fluconazole, Omeprazole, Metronidazole, 
Trioimune40, Septrin, Metochlorpramide, 
Multivitamin, Intravenous fluids. 
 
Because of persistent colicky abdominal pain, 
it was decided to take the patient for 
exploratory laparotomy. The findings 
included multiple purple nodules involving 
the stomach and small bowel wall. There was 
one big mass (6 x 4cm) causing jejunal 
obstruction. There were no mesenteric or 
paraortic lymph node enlargement and the 
rest of the abdominal viscera were normal. 
Resection of the mass causing obstruction, 
end to end anastomosis was done with 
uneventful postoperative recovery.  
 
Histology of biopsy specimen revealed 
“diffuse large cell lymphoma, high grade”. 
The patient was then referred to Ocean Road 
Cancer Institute (ORCI) where he was 
planned for six cycles of second line 
chemotherapy (Doxorubicin, 
Cyclophosphamide, Bleomycinand and 
Prednisolone).He received the first cycle then 
he was discharged home.  
 
He was planned to go back for the second 
cycle after three weeks but he died suddenly 
on the same day of discharge just after arrival 
at home. The cause of death was attributed to 
treatment complications due to advanced 




Clinical features of gastrointestinal 
lymphoma are often vague and non-specific 
leading to delay in diagnosis with poor 
treatment outcome13,14,15. Its presentation 
depends on the tumor size and its location. It 
may present with a single lesion, multiple 
fungating masses or diffuse lesions affecting 
any region from the oral mucosa to the 
rectum. The most frequent location is the 
stomach accounting for 74.7% to be followed 
by small bowel (8.6%) then ileo-caecal region 
(7.0%) and multiple sites (6.5%). The rest of 
regions constitute 3.2 %4. Our patient 
presented with multiple sites involving 
stomach, duodenum, jejunum and ileum. 
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The commonest symptoms include vague 
abdominal pain, nausea, weight loss, 
vomiting and abdominal fullness16,17,18. These 
may mimic other abdominal pathologies such 
as peptic ulcer, pancreatitis, cholecystitis or 
malignancies. Our patient had all these 
symptoms with diarrhoea in addition. Pain is 
the main diagnostic symptom to be followed 
by nausea in both gastric and intestinal 
lymphoma accounting for 78% in gastric and 
53.3% in multiple involvements4. 
Less frequent symptoms include body 
weakness, sweating, jaundice, pyrexia of 
unknown origin and dysphagia16,19,20. Rare 
symptoms include haematemesis or malaena, 
gastric outlet obstruction, and bowel 
perforation15,16. 
 
Physical examination is normal in 55-60% of 
patients16. Common signs include epigastric 
or generalized tenderness and palpable 
mass(es) accounting for 20-35% and 17-25% 
respectively17,20,21. Other uncommon findings 
include pyrexia, hepatosplenomegaly, 
jaundice and lymphadenopathy. Our patient 
had a palpable tender mass. 
 
Diagnostic investigations include barium 
swallow or meal depending on presentation, 
upper or lower gastrointestinal endoscopy + 
step multiple biopsies depending on 
presentation, abdominal ultrasonography, 
abdominal CT scan, Magnetic Resonant 
Imaging (MRI) and Fine Needle Aspiration 
Cytology (FNAC) if present with a mass. 
Barium swallow or meal may show a filling 
defect, atypical ulcer deformities, obstruction, 
mass effect and gastric wall thickening 
suggestive of gastric lymphoma but not 
specific12,16,17,22. Upper GI’ endoscopy 
(OGD) may reveal a range of features which 
vary from subtle mucosal changes to gross 
lesions which include mucosal oedema, 
friability, patchy redness, irregular patchy 
gray or whitish granular easily bleeding, 
irregular erosions and ulcerations12,23. Powtz 
et al1 when evaluating seropositive patients 
with abdominal pain found that out of 93 
endoscopies 7.5% had Non Hodgkin’s 
lymphoma.  
 
Abdominal ultrasonography is helpful in 
evaluating hepatic lesion(s) or in staging 
purposes by identifying involvement of intra-
abdominal lymph node. CT scan of abdomen 
revealed gastric wall thickening or mass 
lesions. It may show mural (horizontal) 
thickening compared to vertical growth in 
carcinoma at early stages of the disease. It 
also reveals peri-gastric, porta-hepatis and 
para-aortic lymph node enlargement, which is 
useful in staging purposes24,25.  
 
Endoscopic ultrasonography may 
differentiate infiltrative carcinomas from 
lymphoma whereby, carcinoma reveal a 
vertical growth compared to horizontal 
growth in early stages as well as perigastric 
lymph nodes in staging purposes26,27. MRI 
reveals irregularly thickening mucosa, 
irregularly submucosal infiltration, annular 
constricting lesion, exophytic tumor growth, 
mesenteric masses and 
mesenteric/retroperitoneal 
lymphadenopathy28. Bone marrow is used for 
staging purposes and indirect laryngoscopy is 
used in assessing Waldeyer’s ring, which is 
common in lymphoma. FNAC by 
experienced Cytologist is helpful in hepatic 
lesion or lymph node23. The above diagnostic 
methods avoid unnecessary exploratory 
laparotomy to confirm the diagnosis and 
staging purposes. 
 
There are several classification systems for 
staging gastrointestinal lymphoma based on 
Ann Arbor Classification. Treatment for 
gastrointestinal NHL depends on the stage 
and grade of the disease as follows4,30,31: 
 
(i) Low- grade lymphoma, stage IE and 
IIE  
Surgical resection then extended field 
radiotherapy with total abdominal 
irradiation with 30 Gy. In case of 
residual tumor, then an additional 
boost (10 Gy) 
In addition to patient with stage IIE, 
six cycles of (COP)- 
Cyclophosphamide 500mg/m2 on 
days 1-5, Vincristine 1.4 mg/m2 on 
day 1 and Prednisone 100mg/m2 on    
days 1-5 preceeding radiotherapy. 
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(ii) Low grade lymphoma, stage IIIE and 
IVE receive COP six cycles only. 
(iii) High grade lymphoma stage IE 
Four cycles of second line 
chemotherapy, which include 
(CHOP)-Cyclophosphamide 750 
mg/m2, Doxorubicin50mg/m2, 
Vincristine 1.4mg/m2, Prednisone 
100mg on days 1-5 followed by 
extended field radiotherapy (30Gy + 
10 Gy boost) on tumor bed. 
(iv) High grade lymphoma stage IIE – 
IVE 
Six cycles of CHOP and additional 
involved field radiotherapy (40 Gy) 
 
 
Table 1.Staging Classification for gastric lymphoma according to Musshof’s criteria29: 
 
Stage                                           Definition 
I E Lymphoma limited to the stomach 
 
II E1 Involvement of stomach and contiguous lymph nodes 
 




Involvement of stomach and lymph nodes on both sides of the diaphragm. 
IV E Haematogenous spread (stomach and one or more extra lymphatic organ or 
tissues. 
 




Table 2. Modified Black-ledge staging system for gastrointestinal lymphomas29: 
 
Stage                                             Definition 
I Tumor confined to GIT without serosal penetration: single primary site. 
Multiple, non-contiguous lesions. 
II Tumor extending into abdomen from primary site: 
• Nodal involvement 
• II1- Local involvement (gastric or mesenteric) 
• II2 – Distant involvement (Para-aortic or paracaval) 
II E Penetration of serosa to involve adjacent structures: 
Enumerate actual size of involvement, e.g. stage II E  (pancreas),  
IIE (Colon), stage IIE-post abdominal wall 
Perforation / peritonitis. 
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When evaluating prognosis and cause of 
death it was found that gastrointestinal 
lymphoma is associated with late 
manifestation of HIV/AIDS with marked 
immunosuppresion and poor prognosis2. 
Gastric and ileocaecal lymphoma had better 
prognosis than small bowel (P=0.04323) and 
when multiple sites involved (P=0.0177). 
Another study revealed that 13 out 20 (65%) 
deaths were related treatment or late 
presentation4. Surgical resection in early 
stages of disease has good outcome with a 5-
year survival rate of 80-93%32,33. Aggressive 
surgery is not indicated due to increased 
morbidity and this does not influence the 
survival34,35. 
 
 Operative mortality was between 3 to 25 % 
with higher rates for palliative resection, 
which were performed for symptomatic relief 
or tumor debulking36. Combination of surgery 
and chemotherapy have shown the survival 
rate of 60-100% for early disease37.Good 
prognosis was associated with low Grade 
disease, age below 65 years, free surgical 
margins in case of complete resection  and 
achievement of initial  complete 
remission38,39,40. Five-year survival rates were 
reported to be 91%for low grade, 73% for 





Early diagnosis of gastrointestinal lymphoma 
is mainly based on a high suspicious index 
and has good treatment outcome. Late 
presentation is associated with marked 
immunosuppression and poor prognosis. 
Randomized trials are needed to clarify 
whether conservative (radiotherapy), surgical 
or combination treatment is more appropriate 
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